NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Lux LJ, Posey RE, Daniels LS, et al. Pharmacokinetic/Pharmacodynamic Measures for Guiding Antibiotic Treatment for Hospital-Acquired Pneumonia [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Nov. (Comparative Effectiveness Reviews, No. 136.)
Pharmacokinetic/Pharmacodynamic Measures for Guiding Antibiotic Treatment for Hospital-Acquired Pneumonia [Internet].
Show details< PrevNext >
Table D-1. Characteristics of included studies (MS Word, 51K)
Table D-2. Characteristics of samples from included studies (MS Word, 44K)
Table D-3. Intervention and comparator components from included studies (MS Word, 45K)
Table D-4. Clinical response and mechanical ventilation outcomes (MS Word, 43K)
Table D-5. Morbidity and mortality outcomes (MS Word, 44K)
Table D-6. Antibiotic-related adverse events (MS Word, 46K)
References for Appendix D
- 1.
- Fahimi F, Ghafari S, Jamaati H, et al. Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia. Indian J Crit Care Med. 2012 Jul;16(3):141–7. [PMC free article: PMC3506071] [PubMed: 23188954]
- 2.
- Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg. 2000 Jun;179(6):436–40. Epub: 2000/09/27. [PubMed: 11004326]
- 3.
- Jaruratanasirikul S, Wongpoowarak W, Kositpantawong N, et al. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia. Int J Antimicrob Agents. 2012 Nov;40(5):434–9. Epub: 2012/09/11. [PubMed: 22959555]
- 4.
- Lorente L, Jimenez A, Martin MM, et al. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents. 2009 May;33(5):464–8. Epub: 2009/01/20. [PubMed: 19150225]
- 5.
- Nicolau DP, McNabb J, Lacy MK, et al. Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clin Drug Invest. 1999;(2):133–9.
- 6.
- Nicolau DP, Lacy MK, McNabb J, et al. Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infect Dis Clin Pract. 1999;8(1):45–9.
- 7.
- Nicolau DP, McNabb J, Lacy MK, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents. 2001 Jun;17(6):497–504. Epub: 2001/06/09. [PubMed: 11397621]
- 8.
- McNabb JJ, Nightingale CH, Quintiliani R, et al. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy. 2001 May;21(5):549–55. Epub: 2001/05/15. [PubMed: 11349744]
- 9.
- Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother. 2007 Sep;51(9):3304–10. Epub: 2007/07/11. [PMC free article: PMC2043189] [PubMed: 17620371]
- 10.
- Scaglione F, Esposito S, Leone S, et al. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J. 2009 Aug;34(2):394–400. Epub: 2009/02/14. [PubMed: 19213786]
- 11.
- Wang D. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrugresistant Acinetobacter baumannii. Int J Antimicrob Agents. 2009;33:290–1. [PubMed: 19091523]
- 12.
- Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991 Dec;100(6):1619–36. Epub: 1991/12/01. [PubMed: 1959406]
- Evidence Tables - Pharmacokinetic/Pharmacodynamic Measures for Guiding Antibioti...Evidence Tables - Pharmacokinetic/Pharmacodynamic Measures for Guiding Antibiotic Treatment for Hospital-Acquired Pneumonia
- Detailed Description of PCA3 and Total PSA Interpretive Analysis - PCA3 Testing ...Detailed Description of PCA3 and Total PSA Interpretive Analysis - PCA3 Testing for the Diagnosis and Management of Prostate Cancer
- Strength of the Evidence Calculator - Strategies to Reduce Cesarean Birth in Low...Strength of the Evidence Calculator - Strategies to Reduce Cesarean Birth in Low-Risk Women
- Management of Colonic DiverticulitisManagement of Colonic Diverticulitis
- Clostridium difficile Infections: Diagnosis, Treatment, and Prevention - Compara...Clostridium difficile Infections: Diagnosis, Treatment, and Prevention - Comparative Effectiveness Review Summary Guides for Clinicians
Your browsing activity is empty.
Activity recording is turned off.
See more...